Fresenius Medical Care AG (NYSE:FMS) Shares Bought by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP raised its holdings in Fresenius Medical Care AG (NYSE:FMS) by 86.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,820 shares of the company’s stock after purchasing an additional 10,600 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Fresenius Medical Care were worth $517,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of FMS. Franklin Resources Inc. increased its stake in Fresenius Medical Care by 3.3% in the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock valued at $1,490,000 after purchasing an additional 2,386 shares during the period. JPMorgan Chase & Co. increased its stake in Fresenius Medical Care by 18.2% in the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock valued at $211,000 after purchasing an additional 1,528 shares during the period. Crossmark Global Holdings Inc. boosted its holdings in shares of Fresenius Medical Care by 2.2% in the fourth quarter. Crossmark Global Holdings Inc. now owns 64,287 shares of the company’s stock valued at $1,456,000 after acquiring an additional 1,398 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Fresenius Medical Care by 15.6% in the fourth quarter. Blue Trust Inc. now owns 14,876 shares of the company’s stock valued at $317,000 after acquiring an additional 2,013 shares in the last quarter. Finally, DAVENPORT & Co LLC boosted its holdings in shares of Fresenius Medical Care by 1.5% in the fourth quarter. DAVENPORT & Co LLC now owns 58,147 shares of the company’s stock valued at $1,316,000 after acquiring an additional 862 shares in the last quarter. 8.37% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently weighed in on FMS. StockNews.com raised shares of Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. Truist Financial lifted their target price on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the company a “hold” rating in a report on Monday, May 12th.

Fresenius Medical Care Stock Up 1.3%

FMS stock opened at $28.76 on Friday. The company has a market cap of $16.87 billion, a P/E ratio of 23.77, a P/E/G ratio of 0.76 and a beta of 0.85. Fresenius Medical Care AG has a 52 week low of $17.93 and a 52 week high of $28.80. The company’s 50-day moving average price is $24.98 and its 200 day moving average price is $23.67. The company has a current ratio of 1.37, a quick ratio of 1.02 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.01. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The company had revenue of $5.54 billion for the quarter, compared to the consensus estimate of $4.71 billion. On average, research analysts expect that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 23rd will be issued a $0.7871 dividend. This represents a dividend yield of 1.9%. The ex-dividend date is Friday, May 23rd. This is an increase from Fresenius Medical Care’s previous annual dividend of $0.44. Fresenius Medical Care’s dividend payout ratio is 49.11%.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.